What is TELA Bio's market cap?

TELA Bio (TELA) has a market capitalization of $29.1M and trades on NASDAQ.

Who are TELA Bio's competitors?

TELA Bio's key competitors include Integra LifeSciences, Becton, Dickinson and Company, Johnson & Johnson, and others. These companies compete in similar markets and product categories.

Who does TELA Bio partner with?

TELA Bio's notable partners include Aroa Biosurgery, Advanced Medical Solutions Limited, MiMedx Group, Inc., and others.

Where is TELA Bio headquartered?

TELA Bio is headquartered in United States of America and employs approximately 227 people. It has been publicly traded since 2019.

TELA Bio

TELA

TELA Bio is a commercial-stage medical technology company that develops and markets advanced soft-tissue reconstruction solutions.

Market cap

$29.1M-62.1%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$19.1MBeat by $462.3K EPS-$0.21Miss by $0.07

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$20.0M

EPS estimate-$0.17

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

AbbVie$453.91B+36.3%

Medtronic$107.81B-8.5%

Becton, Dickinson and Company$43.8B-16.5%

LeMaitre Vascular$2.3B+21.3%

IAR

Integra LifeSciences$1.5B+49.2%

TELA Bio$29.1M-61.3%

Celularity$21.7M-72.4%

By revenue growth

LeMaitre Vascular+13.3%

AbbVie+9.5%

Medtronic+8.4%

Johnson & Johnson+8.1%

Becton, Dickinson and Company+6.4%

IAR

Integra LifeSciences+1.6%

By net margin

LeMaitre Vascular24.35%+4.4pp

Johnson & Johnson21.48%-3.5pp

Medtronic13.2%-0.7pp

AbbVie5.79%-1.5pp

Becton, Dickinson and Company5.33%-2.1pp

IAR

Integra LifeSciences-0.44%+32.4pp

Profile

TELA Bio is a commercial-stage medical technology company that develops and markets advanced soft-tissue reconstruction solutions. The company's core value proposition centers on prioritizing the preservation and restoration of a patient's own anatomy through reinforced tissue matrices that minimize long-term exposure to permanent synthetic materials. By combining biologic materials with polymer reinforcement, the company aims to improve clinical outcomes and provide a strong economic value proposition for surgeons and healthcare institutions.

Competitive position

A specialized challenger in the soft-tissue repair market, leveraging a unique hybrid biologic-synthetic technology and a cost-effective revenue-sharing manufacturing model.

GeographiesUnited States, European Union, United Kingdom

Customer segmentsHospitals, Group Purchasing Organizations (GPOs), Integrated Delivery Networks (IDNs)

Business modelDirect Sales, Distribution, Licensing

SuppliersOvine rumen (sheep forestomach) suppliers, Polymer manufacturers, Contract manufacturing services

CustomersHospitals, Surgical centers, Group Purchasing Organizations, Independent medical distributors

CountryUnited States of America

Listed2019

Employees227.0

CEOAntony Koblish

SectorHealthcare

IndustryMedical - Devices

Websitetelabio.com

FilingsSEC EDGAR

Questions, answered.

What is TELA Bio's market cap?: TELA Bio (TELA) has a market capitalization of $29.1M and trades on NASDAQ.
Who are TELA Bio's competitors?: TELA Bio's key competitors include Integra LifeSciences, Becton, Dickinson and Company, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
Who does TELA Bio partner with?: TELA Bio's notable partners include Aroa Biosurgery, Advanced Medical Solutions Limited, MiMedx Group, Inc., and others.
Where is TELA Bio headquartered?: TELA Bio is headquartered in United States of America and employs approximately 227 people. It has been publicly traded since 2019.